A Multicenter, Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 (ONWARD2)
Latest Information Update: 26 Jun 2025
At a glance
- Drugs Apremilast (Primary) ; ESK-001 (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms ONWARD2
- Sponsors Alumis
Most Recent Events
- 20 Jun 2025 Planned End Date changed from 1 Jun 2026 to 1 Dec 2025.
- 20 Jun 2025 Planned primary completion date changed from 1 May 2026 to 1 Sep 2025.
- 29 May 2025 Status changed from recruiting to active, no longer recruiting.